|
Febrile Neutropenia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Taken together, inconsistencies with the guideline were observed in this prospective evaluation, suggesting that submitting rationalized policies to decrease G-CSF prescription, especially in patients with a lower or intermediate FN risk, yields substantial cost savings.
|
31615347 |
2020 |
|
Febrile Neutropenia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Decisions about G-CSF prophylaxis may be affected by factors other than risk of FN, such as patient choice, practice protocols/guidelines, lack of reimbursement, and insurance coverage.
|
31656028 |
2020 |
|
Febrile Neutropenia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our objective was to estimate, from a US payer perspective, the incremental costs of FN hospitalizations and the total incremental costs associated with PEG-OBI prophylaxis at varying device failure rates over assured FN prophylaxis with daily injections of filgrastim or filgrastim-sndz or a single injection of pegfilgrastim.<b>Methods:</b> Cost simulations comparing prophylaxis with PEG-OBI at failure rates of 1-10% versus assured prophylaxis in cycle 1 of chemotherapy were performed for panels of 10,000 patients with lung cancer treated with cyclophosphamide, doxorubicin, and etoposide (1 analysis) or non-Hodgkin lymphoma (NHL) treated with CHOP or CNOP (2 analyses).
|
31433700 |
2020 |
|
Febrile Neutropenia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Therefore, the aim of this study is to assess the risk of FN by using the Patient Risk Score (PRS) and evaluating G-CSF use and its side effects by a clinical pharmacist at an outpatient clinic.
|
31127438 |
2020 |
|
Febrile Neutropenia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Granulocyte colony-stimulating factor (G-CSF) is recommended if the risk of febrile neutropenia (FN) following from the chosen chemotherapy protocol is ≥20%.
|
31798380 |
2019 |
|
Febrile Neutropenia
|
0.100 |
Biomarker
|
disease |
BEFREE |
The incidence of FN was on the lower end of the range reported in the literature and the SN results provide supportive data on the efficacy of tbo-filgrastim in pediatric patients.
|
31274668 |
2019 |
|
Febrile Neutropenia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Clinical practice guidelines recommend routine prophylactic coverage with granulocyte colony-stimulating factor (G-CSF)-such as pegfilgrastim-for most patients receiving chemotherapy with an intermediate to high risk for FN.
|
31399079 |
2019 |
|
Febrile Neutropenia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Treatment for FN was limited to antibiotics and supportive therapies until filgrastim was approved for use in the 1990s.
|
31408256 |
2019 |
|
Febrile Neutropenia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Adequate GCSF support in hematology and solid tumor patients is important to prevent CIN/FN and related hospitalizations and chemotherapy disturbances.
|
30827127 |
2019 |
|
Febrile Neutropenia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Risks and consequences of travel burden on prophylactic granulocyte colony-stimulating factor administration and incidence of febrile neutropenia in an aged Medicare population.
|
29661043 |
2019 |
|
Febrile Neutropenia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Chemotherapy-induced febrile neutropenia: primary G-CSF prophylaxis indicated during docetaxel cycles.
|
31814585 |
2019 |
|
Febrile Neutropenia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Exposure-safety analyses supported the recommended brentuximab vedotin starting dose (1.2 mg/kg every 2 weeks), and effective management of peripheral neuropathy and neutropenia with dose modification/reduction and febrile neutropenia with granulocyte colony-stimulating factor primary prophylaxis.
|
31152605 |
2019 |
|
Febrile Neutropenia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Recombinant human granulocyte colony stimulating factor (G-CSF) is commonly used as a primary or secondary prophylaxis to reduce the degree and duration of neutropenia in patients at risk of developing chemotherapy-induced neutropenic fever and infectious complications.
|
30959218 |
2019 |
|
Febrile Neutropenia
|
0.100 |
Biomarker
|
disease |
BEFREE |
After G-CSF administration in septic shock patients with chemotherapy-induced FN, PLR may be used as an early prognostic marker for mortality.
|
30148761 |
2019 |
|
Febrile Neutropenia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Compared with pegfilgrastim, there were a higher risk with filgrastim for incidence of febrile neutropenia (FN) (OR [95% CI]: 1.63 [1.07, 2.46]), and a higher risk with short-acting G-CSF (S-G-CSF) biosimilar and lenograstim for incidence of bone pain (BP) (OR [95% CI]: 6.45 [1.10, 65.73], 5.12 [1.14, 26.12], respectively).
|
31653961 |
2019 |
|
Febrile Neutropenia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
An interactive budget impact model was developed to estimate the changes in drug cost associated with projected increases in the market share of tbo-filgrastim from 5% to 10% and of filgrastim-sndz from 10% to 12% (with a corresponding decrease in filgrastim market share from 85% to 78%) for a 1 million-member health plan among patients with nonmyeloid malignancies receiving chemotherapy with a high risk of FN.
|
30084301 |
2019 |
|
Febrile Neutropenia
|
0.100 |
Biomarker
|
disease |
BEFREE |
SV estimates included the cost of G-CSF, FN, chemotherapy relative dose intensity (RDI) less than 85% (RDI<85%), medical spending, and deaths for 3 scenarios: current use (current G-CSF use), targeted use (100% G-CSF use among patients with high FN risk), and reduced use (current G-CSF use reduced by 20% across all FN risk categories).
|
31622064 |
2019 |
|
Febrile Neutropenia
|
0.100 |
Biomarker
|
disease |
BEFREE |
The utilisation of G-CSF was the only independent factor for FN in a binary regression model.
|
31467066 |
2019 |
|
Febrile Neutropenia
|
0.100 |
Biomarker
|
disease |
BEFREE |
The incidence rate of FN was 23.9%.In patients who received G-CSF as primary prophylaxis, FN expression was completely suppressed.
|
31502114 |
2019 |
|
Febrile Neutropenia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Febrile neutropenia (FN) occurred in 1 patient in the pegfilgrastim arm (1 of 33 cycles) and none in the filgrastim arm.
|
31728715 |
2019 |
|
Febrile Neutropenia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Prophylaxis for febrile neutropenia (FN) is recommended for the duration of myelosuppressive chemotherapy in high-risk patients; yet, granulocyte-colony-stimulating factor (G-CSF) discontinuation occurs frequently in clinical practice.
|
30259136 |
2019 |
|
Febrile Neutropenia
|
0.100 |
Biomarker
|
disease |
BEFREE |
This real-world evidence indicates that CIN/FN prophylaxis initiated with biosimilar filgrastim within 24-72 h post-chemotherapy is effective and safe.
|
30343410 |
2019 |
|
Febrile Neutropenia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In docetaxel (DOC)-based chemotherapy, the frequency of febrile neutropenia (FN) and the G-CSF dose administered varied greatly between studies.
|
30998754 |
2019 |
|
Febrile Neutropenia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Granulocyte-colony stimulating factor (G-CSF) is increasingly been used to prevent febrile neutropenia (FN) associated with the administration of chemotherapy for various cancers.
|
31842789 |
2019 |
|
Febrile Neutropenia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Primary prophylaxis with granulocyte colony-stimulating factor significantly reduced the incidence of febrile neutropenia in this study.
|
31329922 |
2019 |